PeerVoice Oncology & Haematology Audio
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 71:10:26
- Mais informações
Informações:
Sinopse
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Episódios
-
![Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?]()
Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?
29/09/2023 Duração: 54minWong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?
-
![David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting]()
David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
29/09/2023 Duração: 44minDavid Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
-
![Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?]()
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
26/09/2023 Duração: 18minGilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
-
![Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC]()
Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC
19/09/2023 Duração: 25minAmit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC
-
![David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma]()
David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma
14/09/2023 Duração: 26minDavid Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma
-
![Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms]()
Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
14/09/2023 Duração: 21minFrank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
-
![Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise]()
Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise
31/07/2023 Duração: 01h15minArndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise
-
![Javier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer]()
Javier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer
24/07/2023 Duração: 22minJavier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer
-
![Joe OSullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses]()
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
18/07/2023 Duração: 08minJoe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
-
![Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations]()
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
18/07/2023 Duração: 16minMichael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
-
![Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?]()
Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
17/07/2023 Duração: 43minJohnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
-
![D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC]()
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC
27/06/2023 Duração: 55minD. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC
-
![Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans]()
Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
27/06/2023 Duração: 18minSara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
-
![Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?]()
Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?
27/06/2023 Duração: 01h14sKevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?
-
![Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice]()
Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice
19/06/2023 Duração: 24minAditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice
-
![Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk]()
Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
19/06/2023 Duração: 30minSara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
-
![Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations]()
Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
19/06/2023 Duração: 25minArndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
-
![Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers]()
Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
13/06/2023 Duração: 20minGeoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
-
![Nick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses]()
Nick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses
18/05/2023 Duração: 25minNick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses
-
![Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?]()
Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?
12/05/2023 Duração: 19minJulia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?
